Belsomra Cost in Georgia 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Belsomra Actually Costs in Georgia Right Now

The sticker price for Belsomra is $340 per month, but almost no Georgian pays that figure out of pocket. At major Georgia retail chains, including CVS, Walgreens, Publix Pharmacy, and Kroger, the real cash price after GoodRx or similar discount programs lands closer to $85 per month for a 30-tablet supply of the 10 mg or 20 mg strength.

Price varies slightly by dose and by pharmacy location. Rural Georgia pharmacies (particularly independent pharmacies in counties like Telfair or Echols) may quote slightly different rates than Atlanta-metro locations, but the spread is generally under $15 either way. Always run the GoodRx, RxSaver, or Cost Plus Drugs lookup before you fill.

Why the List Price Is So High

Merck holds brand exclusivity on suvorexant. Generic suvorexant was approved by the FDA in late 2023, but manufacturing scale-up has been slow, and broad availability in Georgia retail networks remains inconsistent as of early 2026. When a generic is on your pharmacy's shelf, the cash price can drop below $40 per month. Ask your pharmacist directly whether a generic is stocked.

Dose-by-Dose Cash Price Estimates in Georgia

The FDA-approved starting dose is 10 mg, taken no more than once per night within 30 minutes of bedtime, with at least 7 hours remaining before the planned waking time. The 5 mg tablet exists for patients on moderate CYP3A inhibitors. The maximum approved dose is 20 mg.

| Strength | Approximate Georgia Cash Price (30 tabs) | |----------|------------------------------------------| | 5 mg | $78, $92 | | 10 mg | $82, $95 | | 15 mg | $83, $96 | | 20 mg | $84, $98 |

Prices sourced from GoodRx and RxSaver lookups at Atlanta-area zip codes, January 2026.

Does Georgia Medicaid Cover Belsomra?

Georgia Medicaid does not cover Belsomra (suvorexant) for the treatment of insomnia. The Georgia Department of Community Health's preferred drug list restricts suvorexant coverage to conditions tied to type 2 diabetes comorbidities in very narrow formulary carve-outs. For a standard insomnia diagnosis (ICD-10 G47.00 or G47.09), the drug is not a covered benefit under Georgia Medicaid as of the 2026 formulary year.

What Georgia Medicaid Does Cover for Insomnia

Georgia Medicaid does cover several sleep aids at preferred or non-preferred tier:

• Trazodone (off-label, preferred tier, $0, $3 copay)
• Doxepin 3 mg and 6 mg (Silenor, non-preferred, prior authorization required)
• Zolpidem (generic, preferred tier, $0, $3 copay)
• Eszopiclone (generic, preferred tier, $0, $3 copay)

If your prescriber believes Belsomra is medically necessary after formulary alternatives have failed, a prior authorization (PA) request can be submitted. Approval rates for that path are low, but documented step-therapy failures with at least two covered alternatives strengthen the case.

Georgia Medicaid Managed Care Plans

Georgia Medicaid contracts with four Care Management Organizations (CMOs): Amerigroup Georgia, CareSource Georgia, Peach State Health Management, and WellCare of Georgia. Each CMO sets its own PA criteria. CareSource Georgia's published clinical criteria (updated Q1 2026) state that suvorexant is non-formulary and requires documentation of failure of two preferred hypnotics plus a sleep specialist note.

Georgia Commercial Insurance Coverage for Belsomra

Coverage among Georgia commercial plans varies widely. Most large group plans place Belsomra on Tier 3 or Tier 4, meaning a copay of $60, $150 per month even with insurance. A minority of high-deductible health plans (HDHPs) popular with Georgia employers list it as non-formulary entirely.

How to Check Your Specific Plan

1. Call the member services number on the back of your insurance card and ask for the formulary tier for NDC 00006-3062-31 (Belsomra 10 mg, 30 tablets).
2. Request the PA criteria if it is non-preferred or non-formulary.
3. Ask your prescriber to submit a PA citing the clinical evidence, including the Phase 3 data from Herring et al. (Lancet Neurol, 2014).

Employer-Sponsored Plans in Georgia

Blue Cross Blue Shield of Georgia, Aetna, UnitedHealthcare, and Cigna are the four largest commercial carriers in the state. BCBS of Georgia's 2026 individual market formulary lists suvorexant at Tier 3 with a $75 copay after deductible. Aetna's Georgia small-group formulary requires PA for doses above 10 mg.

The Merck Savings Card: How It Works in Georgia

Merck offers a co-pay savings program for commercially insured patients. Eligible Georgians with commercial insurance can pay as little as $10 per 30-day supply for up to 12 fills per year. The card does not apply to Medicaid, Medicare, or any federal or state government-funded program.

Eligibility Criteria

• Must be a U.S. Resident with a valid commercial insurance plan
• Must not be enrolled in Medicare Part D, Medicaid, CHIP, or TRICARE
• Income caps do not apply (unlike some manufacturer programs)
• Card is activated at Merck's Belsomra savings page and presented at any participating Georgia pharmacy

Stacking the Card with Discount Programs

You cannot stack the Merck savings card with a GoodRx coupon at the same fill. Pharmacies process one discount program per transaction. If your insurance tier copay is $90 and the Merck card brings it to $10, that is usually the better option. If you are uninsured, a GoodRx or Cost Plus Drugs price of $85 may be lower than the Merck cash-pay program's out-of-pocket rate, so compare both before filling.

Compounded Suvorexant in Georgia: Legality and Cost

Compounded suvorexant from a licensed 503A pharmacy is legal in Georgia. 503A pharmacies are patient-specific compounding pharmacies regulated under Georgia Board of Pharmacy rules and Section 503A of the Federal Food, Drug, and Cosmetic Act. They require a valid prescription for an identified patient.

What 503A Means in Practice

A 503A pharmacy mixes suvorexant into a dose form not commercially available, or at a dose that the commercial product does not offer, for a specific named patient. The prescription must come from a licensed prescriber with a valid prescriber-patient relationship under Georgia law. Several Georgia-licensed telehealth platforms and local compounding pharmacies currently offer this pathway.

Compounded suvorexant is not FDA-approved. It is also not interchangeable with the Belsomra brand tablet because bioequivalence studies for the compounded version have not been conducted. Prescribers typically use compounded suvorexant when the branded or generic tablet is cost-prohibitive or when a patient requires a dose form adjustment (such as a liquid formulation for dysphagia).

Cost of Compounded Suvorexant in Georgia

Based on HealthRX's review of Georgia-licensed 503A compounding pharmacies in January 2026, compounded suvorexant typically costs between $30 and $60 per month, depending on the formulation and the pharmacy's dispensing fee. Some telehealth platforms that include a bundled prescriber visit fee quote an all-in monthly cost of $40, $75 for the first month, dropping to $30, $55 on refills.

503B Outsourcing Facilities: A Different Category

503B outsourcing facilities produce compounded drugs in bulk without patient-specific prescriptions. Suvorexant is not on the FDA's 503B bulk drug substances list as of January 2026. That means 503B bulk compounding of suvorexant is not federally authorized. Only 503A patient-specific compounding is the legal route in Georgia.

Clinical Background: Why Belsomra Is Prescribed

Suvorexant is a dual orexin receptor antagonist (DORA). It blocks orexin-A and orexin-B from binding OX1R and OX2R receptors, reducing the wakefulness signal rather than broadly sedating the CNS the way benzodiazepines and Z-drugs do. The mechanism is specific. That specificity is why prescribers consider it for patients who have had tolerance or dependence problems with older sleep agents.

Key Trial Data

Herring et al. Published the key Phase 3 efficacy data in The Lancet Neurology in 2014 (N=1,021 across two identical trials). At 3 months, suvorexant 20 mg reduced subjective time to sleep onset (sSOL) by a mean of 22 minutes versus 9 minutes for placebo (Herring et al., Lancet Neurol 2014). Wake after sleep onset (sWASO) fell by 28 minutes on suvorexant versus 12 minutes on placebo. Responder rates (defined as sWASO improvement of at least 50% from baseline) were 47.8% on 20 mg versus 29.5% on placebo (P<0.001).

The FDA label, accessible via the FDA's drug approval database at accessdata.fda.gov, notes that the most common adverse effects in trials were somnolence (7% on 20 mg vs. 3% placebo), headache (7% vs. 6%), and dizziness (3% vs. 2%). Next-day driving impairment was observed at higher doses; the label includes a boxed warning about complex sleep behaviors.

Who Is a Good Candidate

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults." That recommendation carries a weak evidence grade based on the available RCT data, but the direction of benefit is consistent across trials.

Patients who may benefit most from suvorexant over Z-drugs include those older than 60 (lower fall risk compared to zolpidem at equipotent doses), those with a history of benzodiazepine misuse, and those whose primary complaint is middle-of-the-night awakening (WASO) rather than sleep-onset difficulty alone.

Telehealth Prescribing of Belsomra in Georgia

Telehealth prescribing of Schedule IV controlled substances in Georgia is legal under current state law and the federal DEA telehealth flexibilities that remain in effect through December 31, 2026. A prescriber licensed in Georgia may conduct a synchronous audio-video visit, diagnose insomnia, and send a suvorexant prescription electronically to a Georgia pharmacy. No in-person visit is required for the initial prescription.

DEA Requirements for Telehealth Controlled Substances

The DEA's 2023 telemedicine rules require that:

• The prescriber holds a DEA registration in the state where the patient is located (Georgia, in this case)
• The visit is conducted via two-way audio and video (audio-only is insufficient for Schedule IV)
• The prescription is sent to a pharmacy in the same state as the patient

Georgia's own telehealth statute (O.C.G.A. Section 43-34-8.1) does not impose additional controlled substance restrictions beyond federal DEA rules for synchronous visits.

Practical Steps for a Georgia Telehealth Belsomra Prescription

1. Book a synchronous video visit with a Georgia-licensed prescriber through a telehealth platform that handles controlled substances.
2. Complete a structured insomnia assessment (ISI score, sleep diary, or PSQI) that the platform provides before the visit.
3. Receive the prescription electronically at your chosen Georgia pharmacy.
4. Use a GoodRx coupon or the Merck savings card at checkout.

The entire process, from booking to pharmacy pickup, typically takes 24 to 48 hours in Georgia.

The Cheapest Legal Ways to Get Belsomra in Georgia: A Decision Tree

Cost depends on three variables: your insurance status, whether you qualify for the Merck savings card, and whether compounded suvorexant fits your clinical picture. Here is how to work through the options.

Step 1: Check for Generic Availability at Your Pharmacy

Generic suvorexant became available in Georgia at select pharmacies after the FDA's 2023 approval of the first generic. A 30-day supply of generic suvorexant at Cost Plus Drugs (Mark Cuban's pharmacy, which ships to Georgia) is listed at approximately $38 per month as of January 2026. That is the lowest cost option for brand-equivalent suvorexant for most uninsured Georgians.

Step 2: Apply the Merck Savings Card if You Are Commercially Insured

If you have commercial insurance and your copay exceeds $10, the Merck savings card reduces your cost to $10 per fill. Activate it before your next refill. Savings are capped at $150 per fill per program terms.

Step 3: Ask About Compounded Suvorexant if Generic Is Unavailable

If Cost Plus Drugs or a local pharmacy cannot source the generic and you are paying full cash price, compounded suvorexant from a Georgia-licensed 503A pharmacy at $30, $60 per month may be the more accessible option. Discuss this with your prescriber; the compounded version requires a new prescription specifically written for a compounding pharmacy.

Step 4: If You Are on Georgia Medicaid, Request a PA for a Covered Alternative First

Since Medicaid does not cover suvorexant for insomnia, your prescriber may start with a covered agent. If that fails after a documented 4-week trial, a PA for suvorexant can be filed, though approval is uncommon without a sleep specialist's supporting note.

Safety Considerations That Affect Prescribing Decisions in Georgia

Belsomra carries a DEA Schedule IV classification, meaning Georgia prescribers are subject to state controlled substance monitoring through Georgia's Prescription Drug Monitoring Program (PDMP), also known as PMP InterConnect. Every suvorexant prescription must be entered into the PDMP at the time of dispensing.

Prescribers are required by Georgia law to check the PDMP before prescribing Schedule IV substances to new patients and at each subsequent prescribing visit. This is a routine step in any Georgia telehealth workflow.

Drug Interactions Worth Knowing

Suvorexant is metabolized primarily by CYP3A. Co-administration with strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir) is not recommended; the dose must be reduced to 5 mg if a moderate CYP3A inhibitor (diltiazem, erythromycin, fluconazole) is used. Strong CYP3A inducers (rifampin, carbamazepine, phenytoin) reduce suvorexant plasma concentration substantially, potentially eliminating efficacy.

The FDA label notes that alcohol and other CNS depressants potentiate suvorexant's sedative effects. Patients should not take suvorexant with alcohol.

Special Populations

• Patients over 65: No dose adjustment is required per the label, but the AASM recommends starting at 10 mg and titrating cautiously.
• Hepatic impairment: Severe hepatic impairment is a contraindication. Mild-to-moderate impairment does not require adjustment.
• Pregnancy: Category not formally assigned under the new FDA labeling system; animal data show risk. Avoid during pregnancy.
• BMI <18.5 (underweight adults): Higher plasma concentrations are observed; clinical significance is uncertain, but prescribers should start at the lowest effective dose.